Geneoscopy is a healthcare startup that operates in the medical diagnostics market, specifically focusing on gastrointestinal diseases. The company's mission is to empower patients and healthcare providers by offering innovative, non-invasive tests that can detect, prevent, and monitor diseases such as colorectal cancer, ulcerative colitis, and Crohn's disease.

Geneoscopy's business model revolves around its proprietary stool-derived eukaryotic RNA (seRNA) technology platform. In simple terms, this technology allows for the analysis of stool samples to detect signs of disease. This approach is a significant departure from traditional methods like colonoscopies, which are invasive and often inconvenient for patients. As a result, Geneoscopy's tests are safe, effective, and accessible, making them an attractive option for patients and healthcare providers alike.

The company primarily serves patients who are eligible for colorectal cancer screening but have not undergone it due to the invasive nature of traditional methods. With colorectal cancer being the second deadliest cancer in the US, Geneoscopy's services address a significant need in the market.

Geneoscopy generates revenue by selling its diagnostic tests to healthcare providers and patients. The company's commitment to early cancer detection and the increasing acceptance of diagnostics in managing gastrointestinal diseases suggest a promising future for the business.

Keywords: Healthcare, Diagnostics, Gastrointestinal Diseases, Non-Invasive Tests, Colorectal Cancer, Ulcerative Colitis, Crohn's Disease, seRNA Technology, Early Detection, Preventive Medicine.